Eisai has filed a patent for a therapeutic agent to treat fatty liver diseases. The agent includes a compound represented by a specific formula. The patent aims to provide a solution for this medical condition. GlobalData’s report on Eisai gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eisai Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eisai, human telomerase RT biomarker was a key innovation area identified from patents. Eisai's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Therapeutic agent for fatty liver diseases

Source: United States Patent and Trademark Office(USPTO). Credit: Eisai Co Ltd

A recently filed patent (Publication Number: US20230201163A1) discloses a therapeutic agent for the treatment of fatty liver disease. The agent comprises a compound represented by a specific chemical formula (Formula 1). The patent claims that this compound can be used as a therapeutic agent for non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

The patent further specifies that the therapeutic agent can be in the form of a pharmaceutically acceptable salt, with hydrochloride being one example. This suggests that the compound can be formulated into a salt form for better stability and efficacy.

The claims also differentiate between NAFLD and NASH, two related but distinct conditions. NAFLD refers to fatty liver disease without inflammation, while NASH is characterized by both liver inflammation and fat accumulation. The patent claims that the therapeutic agent can be used for both NAFLD and NASH, indicating its potential broad applicability in treating different stages of fatty liver disease.

Additionally, the patent claims that the therapeutic agent can be effective in treating NAFLD or NASH accompanied by liver fibrosis or liver inflammation. This suggests that the compound may have the potential to address the underlying causes and symptoms of these conditions, potentially providing a comprehensive treatment approach.

Overall, this patent filing introduces a therapeutic agent for fatty liver disease, specifically targeting NAFLD and NASH. The compound described in the patent claims has the potential to be formulated as a pharmaceutically acceptable salt and may be effective in treating both NAFLD and NASH, with or without liver fibrosis or inflammation. Further research and development are needed to validate the efficacy and safety of this therapeutic agent in clinical trials.

To know more about GlobalData’s detailed insights on Eisai, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies